Could cocoa help MS fatigue?
Summary
Cocoa is a drink traditionally associated with bedtime, so the idea that it could reduce fatigue in MS might seem unlikely. But cocoa made from dark chocolate contains high levels of flavonoids which have the potential to reduce fatigue through a number of different biological processes. Researchers designed a study to compare fatigue levels after drinking a low flavonoid or a high flavonoid cocoa drink on separate study days.
The study was small (12 participants) and involved just one drink of each type of cocoa. The results did indicate that a single drink of high flavonoid cocoa reduced self-reported fatigue, lead to increased physical activity during waking hours and less activity during sleeping hours, suggesting improved sleep quality.
Building on these preliminary results, the researchers have recently completed a study with 40 participants taking either low or high flavonoid cocoa drink every morning for six weeks. The data from this larger study is now being analysed and written up – we’ll share the results when they are published.
Background
Cocoa is a drink traditionally associated with bedtime, so the idea that it could reduce fatigue in MS might seem unlikely. However, cocoa contains flavonoids, naturally occurring chemicals found in plant-based foods, including dark chocolate with cocoa levels of over 70%. In theory, flavonoids could improve fatigue in a number of different ways. This has never been investigated, so researchers at Oxford Brookes University carried out a small study to test whether drinking cocoa rich in flavonoids might improve fatigue.
How this study was carried out
12 participants with MS fatigue were recruited and asked to attend two study visits. To ensure as much consistency as possible between study days, participants were asked to eat the same diet on the day before each visit, avoid vigorous exercise and to limit their alcohol and caffeine intake on the day prior to testing.
On study days, participants were given either a low flavonoid or a high flavonoid cocoa drink, with at least three days between visits; participants were not aware of which kind of cocoa they were drinking. The two drinks were matched as closely as possible for carbohydrate and energy content. Some of the participants were following a diet which excludes dairy, so the drinks were made with rice milk.
After drinking the cocoa, participants recorded their fatigue level at 30 minute intervals using a visual analogue scale - a 10 cm line labelled “not at all fatigued” at one end and “extremely fatigued” at the other. Distance walked in 6 minutes was measured 2 hours after the drink and physical activity recorded for 24 hours with a wrist-worn activity sensor. Glycaemic response - changes in blood sugar levels – was also monitored for 2 hours after the drink.
What was found
All participants drank and enjoyed the cocoa and were happy with what they were asked to do on each study day. No side effects were reported and neither of the drinks caused an excessive increase in blood sugar levels. In the high flavonoid group, self-reported fatigue levels were moderately improved and 24 hour physical activity was increased. There was more activity during the sleeping hours (10pm-9am) after the low flavonoid cocoa. There was no measureable change in distance walked in 6 minutes.
What does it mean?
The researchers’ primary aim was to test the feasibility of carrying out this type of study rather than generate evidence on the effectiveness of high flavonoid cocoa in reducing fatigue. The study was small (12 participants) and involved just one drink of each type of cocoa. Having said that, the results do suggest that a single drink of high flavonoid cocoa reduced self-reported fatigue, lead to increased physical activity during waking hours and less activity during sleeping hours, suggesting improved sleep quality.
The researchers concluded that the drink was safe and acceptable and that the encouraging, preliminary results merited further investigation. They have recently completed a study with 40 participants taking either low or high flavonoid cocoa drink every morning for six weeks. The data from this larger study are now being analysed and written up – we’ll share the results when they are published.
Coe S, et al.
Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: An exploratory trial.
Clinical Nutrition ESPEN 2017; 21: 20-25.
Abstract
More about how diet and nutrition can help with fatigue
A healthy, well balanced diet with plenty of fruit and vegetables plus complex carbohydrates, some protein-rich foods such as meat, fish and lentils and not too much fat, salt or sugar is required to provide optimum energy levels. A poor diet or eating habits can leave the body lacking in the fuel needed to get through the day. Although food and drinks high in sugar give an initial boost, blood sugar levels quickly drop again leaving your energy levels low. High sugar foods and drinks are often low in nutrients, and the extra calories can cause unwanted weight gain.
The rate at which sugars are released from foods is called the glycaemic index (GI). Meals and snacks, which are rich in complex carbohydrates such as milk, fresh fruit, yoghurt and multigrain bread have a low glycaemic index, giving a slower, more sustained energy release. Taking a low GI food at the same time as a high GI food can slow down the rate of release, for instance a glass of milk with a sweet biscuit.
It is also very important to drink sufficient fluids, especially water. Being even mildly dehydrated can cause tiredness and sluggishness. Some people with MS restrict the amount of fluid they drink as they are concerned about bladder problems. However, too little fluid can increase the risk of urine infections, headaches and constipation, and thus worsen existing MS symptoms.
Trying to maintain a healthy weight is also helpful as being overweight or underweight can increase fatigue.
When you are struggling with MS fatigue, preparing and eating meals can be a problem too. Our book, Living with fatigue, suggests ways to tackle this.
Research by topic areas...
Causes of MS
Antonazzo IC, Raschi E, Forcesi E, et al.
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.
Expert Opin Drug Saf. 2018 Aug 11:1-6. [Epub ahead of print]
abstract
Kearns PKA, Casey HA, Leach JP.
Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons.
Mult Scler Relat Disord. 2018 Jul 4;24:157-174. [Epub ahead of print]
abstract
Hedström AK, Hössjer O, Katsoulis M, et al.
Organic solvents and MS susceptibility: Interaction with MS risk HLA genes.
Neurology. 2018 Jul 31;91(5):e455-e462.
abstract
Read the full text of this paper
Gallagher LG, Ilango S, Wundes A, et al.
Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
Mult Scler. 2018 Jun 1:1352458518783343. [Epub ahead of print]
abstract
Co-existing conditions
Ning P, Hu F, Yang B, et al.
Systematic review and meta-analysis of observational studies to understand the prevalence of restless legs syndrome in multiple sclerosis: an update.
Sleep Med. 2018 Jun 20;50:97-104. [Epub ahead of print]
abstract
Saroufim P, Zweig SA, Conway DS, et al.
Cardiovascular conditions in persons with multiple sclerosis, neuromyelitis optica and transverse myelitis.
Mult Scler Relat Disord. 2018 Jul 10;25:21-25. [Epub ahead of print]
abstract
Newman JM, Khlopas A, Sodhi N, et al.
Are adverse outcome rates higher in multiple sclerosis patients after total hip arthroplasty?
Bone Joint J. 2018 Jul;100-B(7):875-881.
abstract
Diagnosis
Di Stadio A, Dipietro L, Ralli M, et al.
Sudden hearing loss as an early detector of multiple sclerosis: a systematic review.
Eur Rev Med Pharmacol Sci. 2018 Jul;22(14):4611-4624.
abstract
Wijnands JM, Zhu F, Kingwell E, et al.
Five years before multiple sclerosis onset: Phenotyping the prodrome.
Mult Scler. 2018 Jul 1:1352458518783662. [Epub ahead of print]
abstract
Hagens MHJ, Burggraaff J, Kilsdonk ID, et al.
Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.
Neurology. 2018 Jul 17;91(3):e249-e257.
abstract
Read the full text of this paper
Disease modifying drugs
Boyko AN, Boyko OV.
Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.
Degener Neurol Neuromuscul Dis. 2018 May 3;8:35-44.
abstract
Read the full text of this paper
Sedal L, Winkel A, Laing J, et al.
Current concepts in multiple sclerosis therapy.
Degener Neurol Neuromuscul Dis. 2017 Sep 28;7:109-125.
abstract
Read the full text of this paper
Hendin B, Naismith RT, Wray SE, et al.
Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
Patient Prefer Adherence. 2018 Jul 20;12:1289-1297.
abstract
Read the full text of this paper
Saccà F, Lanzillo R, Signori A, et al.
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
Mult Scler. 2018 Jul 25:1352458518790390. [Epub ahead of print]
abstract
Metze C, Winkelmann A, Loebermann M, et al.
Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.
CNS Neurosci Ther. 2018 Jul 25. [Epub ahead of print]
abstract
Houtchens MK, Bove R.
A case for gender-based approach to multiple sclerosis therapeutics.
Front Neuroendocrinol. 2018 Jul 21. pii: S0091-3022(18)30082-7. [Epub ahead of print]
abstract
Setayeshgar S, Kingwell E, Zhu F, et al.
Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Mult Scler Relat Disord. 2018 Jul 9;25:57-60. [Epub ahead of print]
abstract
Cascione M, Tenenbaum N, Wendt J, et al.
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Mult Scler Relat Disord. 2018 Jul 11;25:50-56. [Epub ahead of print]
abstract
Read the full text of this paper
Zhang Y, Salter A, Cutter G, et al.
Clinical trials in multiple sclerosis: milestones.
Ther Adv Neurol Disord. 2018 Jul 9;11:1756286418785499.
abstract
Read the full text of this paper
Romeo MAL, Martinelli V, Dalla Costa G, et al.
Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.
Acta Neurol Scand. 2018 Jul 22. [Epub ahead of print]
abstract
Mirabella M, Prosperini L, Lucchini M, et al.
Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study.
CNS Drugs. 2018 Jul 18. [Epub ahead of print]
abstract
Naegelin Y, Rasenack M, Andelova M, et al.
Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
Mult Scler Relat Disord. 2018 Jul 6;25:14-20. [Epub ahead of print]
abstract
Read the full text of this paper
Lucchetta RC, Tonin FS, Borba HHL, et al.
Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis.
CNS Drugs. 2018 Jul 16. [Epub ahead of print]
abstract
Alnajashi HA, Alshamrani FJ, Freedman MS.
Tolerability and discontinuation rates in teriflunomide-treated patients. A real-world clinical experience.
Neurosciences (Riyadh). 2018 Jul;23(3):204-207.
abstract
Reen GK, Silber E, Langdon DW.
Best methods of communicating clinical trial data to improve understanding of treatments for patients with multiple sclerosis.
Value Health. 2018 Jul;21(7):762-766.
abstract
Rasmussen PV, Magyari M, Moberg JY, et al.
Patient awareness about family planning represents a major knowledge gap in multiple sclerosis.
Mult Scler Relat Disord. 2018 Jun 15;24:129-134. [Epub ahead of print]
abstract
Read the full text of this paper
Schreiber K, Kant M, Pfleger C, et al.
High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open-label Danish study.
Patient Prefer Adherence. 2018 Jun 29;12:1139-1150.
abstract
Read the full text of this paper
Oshima Y, Tanimoto T, Yuji K, et al.
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Mult Scler. 2018 Jul 9:1352458518786075. [Epub ahead of print]
abstract
Yamout BI, Sahraian MA, Ayoubi NE, et al.
Efficacy and safety of natalizumab extended interval dosing.
Mult Scler Relat Disord. 2018 Jul 5;24:113-116. [Epub ahead of print]
abstract
Robertson D, Aungst A, Collier R, et al.
Patient perceived changes in sexual dysfunction after initiation of natalizumab for multiple sclerosis.
Mult Scler J Exp Transl Clin. 2018 Jun 12;4(2):2055217318781989.
abstract
Read the full text of this paper
Zecca C, Bellavia G, Brambilla L, et al.
Atypical post-injection reactions with delayed onset following glatiramer acetate 40 mg: need for titration?
CNS Drugs. 2018 Jul;32(7):653-660.
abstract
Drugs in development
Cohen JA, Comi G, Arnold DL, et al.
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler. 2018 Jul 25:1352458518789884. [Epub ahead of print]
abstract
Read the full text of this paper
Gold J, Marta M, Meier UC, et al.
A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.
Mult Scler Relat Disord. 2018 Jun 28;24:123-128. [Epub ahead of print]
abstract
De Angelis F, Plantone D, Chataway J.
Pharmacotherapy in secondary progressive multiple sclerosis: an overview.
CNS Drugs. 2018 Jun;32(6):499-526.
abstract
Uitdehaag BMJ.
Disability outcome measures in phase III clinical trials in multiple sclerosis.
CNS Drugs. 2018 Jun 20. [Epub ahead of print]
abstract
Read the full text of this paper
Economics
Murley C, Yang F, Gyllensten H, et al.
Disposable income trajectories of working-aged individuals with diagnosed multiple sclerosis.
Acta Neurol Scand. 2018 Jul 24. [Epub ahead of print]
abstract
Families
Landfeldt E, Castelo-Branco A, Svedbom A, et al.
The long-term impact of multiple sclerosis on the risk of divorce.
Mult Scler Relat Disord. 2018 Jul 3;24:145-150. [Epub ahead of print]
abstract
Other treatments
Keyhani S, Steigerwald S, Ishida J, et al.
Risks and benefits of marijuana use: a national survey of U.S. adults.
Ann Intern Med. 2018 Jul 24. [Epub ahead of print]
abstract
Tullman M, Chartier-Kastler E, Kohan A, et al.
Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS.
Neurology. 2018 Aug 14;91(7):e657-e665.
abstract
Read the full text of this paper
Sola-Valls N, Blanco Y, Sepúlveda M, et al.
Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine.
Ther Adv Neurol Disord. 2018 Jun 10;11:1756286418780007.
abstract
Read the full text of this paper
Turri M, Teatini F, Donato F, et al.
Pain modulation after oromucosal cannabinoid spray (Sativex®) in patients with multiple sclerosis: a study with quantitative sensory testing and laser-evoked potentials.
Medicines (Basel). 2018 Jun 21;5(3). pii: E59.
abstract
Read the full text of this paper
Paediatric MS
Wilbur C, Yeh EA.
Radiologically isolated syndrome in children: Current knowledge and future directions.
Mult Scler Relat Disord. 2018 Jun 21;24:79-84. [Epub ahead of print]
abstract
Pregnancy and childbirth
Tong Y, Liu J, Yang T, et al.
Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis.
Mult Scler Relat Disord. 2018 Jul 6;25:61-65. [Epub ahead of print]
abstract
Harazim H, Štourač P, Janků P, et al.
Obstetric anesthesia/analgesia does not affect disease course in multiple sclerosis: 10-year retrospective cohort study.
Brain Behav. 2018 Jul 25:e01082. [Epub ahead of print]
abstract
Read the full text of this paper
Interferon beta.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
abstract
Read the full text of this paper
Glatiramer.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
abstract
Read the full text of this paper
Peginterferon beta.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
abstract
Read the full text of this paper
Landi D, Ragonese P, Prosperini L, et al.
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2018 Jul 3. pii: jnnp-2018-318468. [Epub ahead of print]
abstract
Prognosis
Balloy G, Pelletier J, Suchet L, et al.
Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
J Neurol. 2018 Jul 27. [Epub ahead of print]
abstract
D'Amico E, Patti F, Zanghì A, et al.
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
Eur J Neurol. 2018 Jun 28. [Epub ahead of print]
abstract
Provision of care
Saposnik G, Tobler PN, Caceres F, et al.
Usability of an educational intervention to overcome therapeutic inertia in multiple sclerosis care.
Front Neurol. 2018 Jul 10;9:522.
abstract
Read the full text of this paper
Giovannetti AM, Borreani C, Bianchi E, et al.
Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study.
PLoS One. 2018 Jul 12;13(7):e0200532.
abstract
Read the full text of this paper
Leclerc-Loiselle J, Legault A.
Introduction of a palliative approach in the care trajectory among people living with advanced MS: perceptions of home-based health professionals.
Int J Palliat Nurs. 2018 Jun 2;24(6):264-270.
abstract
Psychological aspects
Alschuler KN, Arewasikporn A, Nelson IK, et al.
Promoting resilience in individuals aging with multiple sclerosis: Results from a pilot randomized controlled trial.
Rehabil Psychol. 2018 Aug;63(3):338-348.
abstract
Senders A, Hanes D, Bourdette D, et al.
Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
Mult Scler. 2018 Jul 1:1352458518786650. [Epub ahead of print]
abstract
Gromisch ES, Fiszdon JM, Kurtz MM.
The effects of cognitive-focused interventions on cognition and psychological well-being in persons with multiple sclerosis: A meta-analysis.
Neuropsychol Rehabil. 2018 Jul 5:1-20. [Epub ahead of print]
abstract
Rehabilitation
Prosperini L, Castelli L.
Spotlight on postural control in patients with multiple sclerosis.
Degener Neurol Neuromuscul Dis. 2018 Apr 3;8:25-34.
abstract
Read the full text of this paper
Bisht B, Darling WG, White EC, et al.
Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study.
Degener Neurol Neuromuscul Dis. 2017 Jun 26;7:79-93.
abstract
Read the full text of this paper
Mañago MM, Hebert JR, Kittelson J, et al.
Feasibility of a targeted strengthening program to improve gait in people with multiple sclerosis: a brief report.
Int J Rehabil Res. 2018 Jul 23. [Epub ahead of print]
abstract
Learmonth YC, Kinnett-Hopkins D, Motl RW.
Capitalising on the opinions of persons with multiple sclerosis to inform the main trial - participant opinions from participation in a feasibility study, a qualitative extension study.
Disabil Rehabil. 2018 Jul 24:1-8. [Epub ahead of print]
abstract
Lahelle AF, Øberg GK, Normann B.
A group-based, individualized physiotherapy intervention for people with multiple sclerosis-A qualitative study.
Physiother Res Int. 2018 Jul 23:e1734. [Epub ahead of print]
abstract
Moumdjian L, Gervasoni E, Van Halewyck F, et al.
Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis.
Int J Rehabil Res. 2018 Jul 16. [Epub ahead of print]
abstract
Cetisli Korkmaz N, Can Akman T, Kilavuz Oren G, et al.
Trunk control: The essence for upper limb functionality in patients with multiple sclerosis.
Mult Scler Relat Disord. 2018 Jun 28;24:101-106. [Epub ahead of print]
abstract
Kalron A, Aloni R, Givon U, et al.
Fear of falling, not falls, impacts leisure-time physical activity in people with multiple sclerosis.
Gait Posture. 2018 Sep;65:33-38.
abstract
Carling A, Nilsagård Y, Forsberg A.
Balance exercise facilitates everyday life for people with multiple sclerosis: A qualitative study.
Physiother Res Int. 2018 Jul 1:e1728. [Epub ahead of print]
abstract
Read the full text of this paper
Martini DN, Zeeboer E, Hildebrand A, et al.
ADSTEP: Preliminary investigation of a multicomponent walking aid program in people with multiple sclerosis.
Arch Phys Med Rehabil. 2018 Jun 26. pii: S0003-9993(18)30382-4. [Epub ahead of print]
abstract
Moffat F, Paul L.
Barriers and solutions to participation in exercise for moderately disabled people with multiple sclerosis not currently exercising: a consensus development study using nominal group technique.
Disabil Rehabil. 2018 Jun 29:1-9. [Epub ahead of print]
abstract
Fakolade A, Latimer-Cheung A, Parsons T, et al.
A concerns report survey of physical activity support needs of people with moderate-to-severe MS disability and family caregivers.
Disabil Rehabil. 2018 Jun 29:1-12. [Epub ahead of print]
abstract
Felippe LA, Salgado PR, Silvestre DS, et al.
A controlled clinical trial on the effects of exercise on cognition and mobility in adults with multiple sclerosis.
Am J Phys Med Rehabil. 2018 Jun 21. [Epub ahead of print]
abstract
Stem cells
Genc B, Bozan HR, Genc S, et al.
Stem cell therapy for multiple sclerosis.
Adv Exp Med Biol. 2018 Jul 24. [Epub ahead of print]
abstract
Symptoms and symptom management
Barin L, Salmen A, Disanto G, et al.
The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
Mult Scler Relat Disord. 2018 Jul 21;25:112-121. [Epub ahead of print]
abstract
Feenaughty L, Tjaden K, Weinstock-Guttman B, et al.
Separate and combined influence of cognitive impairment and dysarthria on functional communication in multiple sclerosis.
Am J Speech Lang Pathol. 2018 Aug 6;27(3):1051-1065.
abstract
Braley TJ.
Overview: a framework for the discussion of sleep in multiple sclerosis.
Curr Sleep Med Rep. 2017 Dec;3(4):263-271. Epub 2017 Oct 28.
abstract
Bigder MG, Krishnan S, Cook EF, et al.
Microsurgical rhizotomy for trigeminal neuralgia in MS patients: technique, patient satisfaction, and clinical outcomes.
J Neurosurg. 2018 Jul 13:1-12. [Epub ahead of print]
abstract
Read the full text of this paper
Tornic J, Panicker JN.
The management of lower urinary tract dysfunction in multiple sclerosis.
Curr Neurol Neurosci Rep. 2018 Jun 28;18(8):54.
abstract
Read the full text of this paper
Work
Vijayasingham L, Mairami FF.
Employment of patients with multiple sclerosis: the influence of psychosocial-structural coping and context.
Degener Neurol Neuromuscul Dis. 2018 Mar 26;8:15-24.
abstract
Read the full text of this paper
Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 Feb 2021 - 00:00
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.
Exercise is good for your brain
3 Feb 2021 - 00:00
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.
Covid-19 vaccines and MS: Part two
29 Jan 2021 - 00:00
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.
Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.
David's Diary- Should we all be saying yes to the Covid 19 vaccine?
18 Feb 2021 - 00:00
For the last few weeks our Enquiry Service at the MS Trust has been busy with questions about the vaccination. In his latest blog piece for the MS Trust, CEO David Martin asks the question, 'Should we all be saying yes to the Covid 19 vaccine?'
Monkey sox are back!
17 Feb 2021 - 00:00
...but this time they've gone casual! We are very excited to have partnered once again with Monkey Sox to bring you an exclusive MS Trust design.
Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.
Share
